NCT01431534 2019-03-01
MK-8669-056
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
3 trialsNCT01431547 2016-06-17
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00781846 2015-02-13
Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed